Találati lista | Tudóstér

001-es BibID:	BIBFORM110898
035-os BibID:	(cikkazonosító)1218 (WoS)000977128900001 (Scopus)85153720382
Első szerző:	Nagy Nikolett (belgyógyász)
Cím:	Changes in Clinical Manifestations and Course of Systemic Lupus Erythematosus and Secondary Antiphospholipid Syndrome over Three Decades / Nagy Nikolett, Papp Gábor, Gáspár-Kiss Eszter, Diószegi Ágnes, Tarr Tünde
Dátum:	2023
ISSN:	2227-9059
Megjegyzések:	Systemic lupus erythematosus (SLE) is often associated with antiphospholipid syndrome (APS), which potentially results in a more severe disease course and reduced life expectancy. Since the therapeutic guidelines have been refined in the last 15 years, we assumed that the diseases course has become more favorable. In order to shed light on these achievements, we compared the data of SLE patients diagnosed before and since 2004. In our retrospective study, we assessed a wide spectrum of clinical and laboratory data of 554 SLE patients who received regular follow-up care and therapy at our autoimmune center. Among these patients, 247 had antiphospholipid antibodies (APAs) without clinical signs of APS, and 113 had definitive APS. In the APS group, among patients diagnosed since 2004, deep vein thrombosis (p = 0.049) and lupus anticoagulant positivity (p = 0.045) were more frequent, while acute myocardial infarction was less frequent (p = 0.021) compared with patients diagnosed before 2004. Among the APA positive patients without definitive APS, anti-cardiolipin antibody positivity (p = 0.024) and development of chronic renal failure (p = 0.005) decreased in patients diagnosed since 2004. Our study demonstrates that the disease course has changed in recent years; however, in the presence of APS, we have to expect repeated thrombotic events despite adequate anticoagulant therapy.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk systemic lupus erythematosus antiphospholipid syndrome disease course therapy
Megjelenés:	Biomedicines. - 11 : 4 (2023), p. 1-10. -
További szerzők:	Papp Gábor (1984-) (belgyógyász) Gáspár-Kiss Eszter (1997-) (rezidens) Diószegi Ágnes (1987-) (belgyógyász) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus)
Pályázati támogatás:	K 124177 NKFIH
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM122040
Első szerző:	Sztanek Ferenc (orvos)
Cím:	New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists / Sztanek Ferenc, Tóth László Imre, Pető Attila, Hernyák Marcell, Diószegi Ágnes, Harangi Mariann
Dátum:	2024
ISSN:	2227-9059
Megjegyzések:	Guidelines for the management of obesity and type 2 diabetes (T2DM) emphasize the importance of lifestyle changes, including a reduced-calorie diet and increased physical activity. However, for many people, these changes can be difficult to maintain over the long term. Medication options are already available to treat obesity, which can help reduce appetite and/or reduce caloric intake. Incretin-based peptides exert their effect through G-protein-coupled receptors, the receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), and glucagon peptide hormones are important regulators of insulin secretion and energy metabolism. Understanding the role of intercellular signaling pathways and inflammatory processes is essential for the development of effective pharmacological agents in obesity. GLP-1 receptor agonists have been successfully used, but it is assumed that their effectiveness may be limited by desensitization and downregulation of the target receptor. A growing number of new agents acting on incretin hormones are becoming available for everyday clinical practice, including oral GLP-1 receptor agonists, the dual GLP-1/GIP receptor agonist tirzepatide, and other dual and triple GLP-1/GIP/glucagon receptor agonists, which may show further significant therapeutic potential. This narrative review summarizes the therapeutic effects of different incretin hormones and presents future prospects in the treatment of T2DM and obesity.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk G-protein-coupled receptors GLP-1 receptor agonist GIP receptor agonist glucagon receptor agonist obesity type 2 diabetes
Megjelenés:	Biomedicines. - 12 : 6 (2024), p. 1-22. -
További szerzők:	Tóth László (1997-) (orvos) Pető Attila (1990-) (általános orvos) Hernyák Marcell Diószegi Ágnes (1987-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus)
Pályázati támogatás:	142273 OTKA TKP2021-EGA-18 Egyéb Eötvös Loránd Research Network 11003 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: